AustralianSuper Pty Ltd Has $66.96 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

AustralianSuper Pty Ltd lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 577.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 189,780 shares of the biotechnology company’s stock after buying an additional 161,751 shares during the quarter. AustralianSuper Pty Ltd owned about 0.43% of United Therapeutics worth $66,962,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of United Therapeutics by 4.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock worth $391,459,000 after buying an additional 45,566 shares during the period. FMR LLC grew its position in shares of United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after buying an additional 314,004 shares during the period. Pacer Advisors Inc. grew its position in shares of United Therapeutics by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after buying an additional 30,931 shares during the period. Janus Henderson Group PLC grew its holdings in United Therapeutics by 12.3% during the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock valued at $164,978,000 after purchasing an additional 50,409 shares during the period. Finally, Assetmark Inc. grew its holdings in United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after purchasing an additional 152,249 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of analyst reports. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Argus boosted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. TD Cowen boosted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, LADENBURG THALM/SH SH boosted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $382.08.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares in the company, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 121,864 shares of company stock valued at $44,516,965 over the last 90 days. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Stock Up 0.0 %

Shares of UTHR stock opened at $370.58 on Friday. The company’s fifty day simple moving average is $361.93 and its 200-day simple moving average is $358.65. The firm has a market cap of $16.55 billion, a PE ratio of 16.27, a P/E/G ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a 12 month low of $211.61 and a 12 month high of $417.82.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.